Health Technology · Pharmaceuticals: Major · NSE: AJANTPHARM · data 2026-10-09

Ajanta Pharma Limited

Health check: Strong (8.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹3,410.1

Market cap

₹42,952 cr

P/E

37.6

P/B

—

ROE

25.4%

ROCE

30.0%

Debt / equity

0.06

Dividend yield

1.75%

1-year return

41.0%

52-week high

₹3,796

52-week low

₹2,380.2

Operating margin

24.3%

Growth

Revenue (last 12 months)	₹5,776 cr
Net profit (last 12 months)	₹1,135 cr
Sales growth, 3 years (yearly)	13.3%
Profit growth, 3 years (yearly)	21.6%

Chart patterns

Double top — breakdown (key level ₹3,425)

Similar companies

Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO) · Emcure Pharmaceuticals Limited (EMCURE)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open AJANTPHARM in NSE Scanner →